Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Daniel Anscher, MD, Ahmad El-Far, MD, Said M Baidas

Blood (2019) 134 (Supplement_1): 3417.

https://doi.org/10.1182/blood-2019-121558

Published: 2019

Journal Articles

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Heiko Schoder, MD, Jisun Lee, Theresa Davey, MMSc, PA-C, Helen Hancock, ANP, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, M. Lia Palomba, MD, Gunjan L. Shah, MDMS, Miguel-Angel Perales, MD, Craig S. Sauter, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 1555.

https://doi.org/10.1182/blood-2019-129364

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Steven M. Bair, MD, Rahul Banerjee, MD, Charalambos Andreadis, MD, Tatyana A. Feldman, MD, Elizabeth L. McCarthy, MSN, RN, Niloufer Khan, MD, Alison J. Moskowitz, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Sarah J. Nagle, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J Schuster, MD

Blood (2019) 134 (Supplement_1): 2855.

https://doi.org/10.1182/blood-2019-123741

Published: 2019

Journal Articles

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Emily C. Ayers, MD, David J Margolis, MD, Phyllis A. Gimotty, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 2893.

https://doi.org/10.1182/blood-2019-128815

Published: 2019

Journal Articles

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Ya Hwee Tan, MBBS, MRCP, Siqin Zhou, MSc, Liu Xin, Soon Thye Lim, MBBS, MRCP, FAMS, Miriam Tao, MBBS, FAMS, FHKAM, FHKCP, MRCP, Daryl Tan, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Mohamad Farid, MBBS, MMed, MRCP, Colin Phipps Diong, Yuh Shan Lee, Shin-Yeu Ong, MD, Nicholas Francis Grigoropoulos, Kheng Wei Yeoh, MBBS, MSc, MRCP, MPH, FRCR (Clinical Oncology), Nagavalli Somasundaram, MBBS, MRCP, Eileen Yi Ling Poon, MBBS, MRCP, MMED, Jason Yongsheng Chan, MBBS, MRCP, Esther Wei Yin Chang, MD MRCP, Tiffany Tang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 5274.

https://doi.org/10.1182/blood-2019-125085

Published: 2019

Journal Articles

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

Ahmad S Halwani, MD, Kelli M Rasmussen, MS, Vikas Patil, MS, Catherine Li, PhD, Christina Young, MA, Zachary Burningham, PhD, Mathias Schulz, MD MBA, Jia Li, PhD, Anthony Masaquel, PhD MPH, Mary Halloran, PharmD, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2018) 132 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2018-99-116695

Published: 2018

Journal Articles

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Sumera Khan, MSc, MD, Kyle Runckel, BS, Cory Mavis, BSc, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2018-99-118480

Published: 2018

Journal Articles

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Anem Waheed, MD MPH, Angie Mae Rodday, PhD MS, Anita J Kumar, MD MS, Kenneth B. Miller, MD, Susan K Parsons, MD MRP

Blood (2018) 132 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2018-99-111921

Published: 2018

Journal Articles

Serum Beta-2 Microglobulin Predicts the Survival Outcome after Autologous Stem Cell Transplantation in Relapse or Refractory Diffuse Large B Cell Lymphoma

Hyeun-Su Im, MD, Jung Yong Hong, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Sang Wook Lee, Chan-Sik Park, Jin-Sook Ryu, Jooryung Huh, Cheolwon Suh

Blood (2018) 132 (Supplement 1): 5755.

https://doi.org/10.1182/blood-2018-99-120334

Published: 2018

Journal Articles

High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Jaewon Hyung, MD, Jung Yong Hong, MD, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Chan-Sik Park, Sang Wook Lee, Jin-Sook Ryu, Jooryung Huh, Cheolwon Suh

Blood (2018) 132 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2018-99-118222

Published: 2018

Journal Articles

Cost Consideration of Second Line Therapy for Relapsed Diffuse Large Lymphoma in the Community Setting

Danny Landau, MD, Brandon Wilds, PharmD, Sammy Mouslly

Blood (2018) 132 (Supplement 1): 5854.

https://doi.org/10.1182/blood-2018-99-111176

Published: 2018

Journal Articles

High-Dose Ara-C, Carboplatin, Etoposide, and Steroids (ACES) Is Effective in Relapse and Refractory Non-Hodgkin Lymphoma

Nobuyuki Kabasawa, MD, Bungo Saito, MD PhD, Yohei Sasaki, MD, Shotaro Shimada, MD, Maasa Abe, MD, So Murai, MD, Yuta Baba, MD, Megumi Watanuki, MD, Yukiko Kawaguchi, MD, Nana Arai, MD, Shun Fujiwara, MD, Hiroyuki Tsukamoto, MDPhD, Yui Uto, MD PhD, Hirotsugu Ariizumi, MD, Kouji Yanagisawa, MD, Norimichi Hattori, MD PhD, Hiroshi Harada, MD, Tsuyoshi Nakamaki, MD PhD

Blood (2017) 130 (Supplement 1): 2850.

https://doi.org/10.1182/blood.V130.Suppl_1.2850.2850

Published: 2017

Journal Articles

Salvage Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Jaewon Hyung, MD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Kyoungmin Lee, MD, Shin Kim, RN, Chan-Sik Park, Jooryung Huh, MD PhD, Jin-Sook Ryu, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 5506.

https://doi.org/10.1182/blood.V130.Suppl_1.5506.5506

Published: 2017

Journal Articles

OPEC/Mpec for Adult T-Cell Leukemia/Lymphoma: A Single-Institution Study

Daisuke Nakamura, MD, PhD, Makoto Yoshimitsu, MD, PhD, Tomohisa Tabuchi, MD, Naosuke Arima, MD, Maiko Hayashida, MD, Hirosaka Inoue, MD, Kakushi Matsushita, MD, PhD, Tadashi Matsumoto, MD, PhD, Naomichi Arima, MD, PhD, Kenji Ishitsuka, MD, PhD

Blood (2016) 128 (22): 1828.

https://doi.org/10.1182/blood.V128.22.1828.1828

Published: 2016

Journal Articles

AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

Erin Gourley Reid, MD, David Looney, MD, Frank Maldarelli, MD PhD, Ariela Noy, MD, David H. Henry, MD, David M. Aboulafia, MD, Juan Carlos Ramos, MD, Joseph Sparano, MD, Richard F. Ambinder, MD PhD, Jeannette Lee, PhD, Ronald T. Mitsuyasu, MD, William Wachsman, MD PhD

Blood (2016) 128 (22): 786.

https://doi.org/10.1182/blood.V128.22.786.786

Published: 2016

Journal Articles

Immune System Profiling Following Autologous Stem Cell Transplant for High-Risk Neuroblastoma Predicts Disease-Free Survival

Michele L Nassin, MD, Elitsa V Nicolaou, MD, Hillary M Hecktman, CPNP-AC, Caitlin W Cohen, CPNP-AC, Susan L Cohn, MD, John M Cunningham, MD, James L LaBelle, MD PhD

Blood (2016) 128 (22): 2251.

https://doi.org/10.1182/blood.V128.22.2251.2251

Published: 2016

Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Craig H Moskowitz, Michelle A Fanale, Bijal D Shah, Ranjana H Advani, MD, Robert Chen, Stella Kim, Ana Kostic, Tina Liu, Joanna Peng, Andres Forero-Torres

Blood (2015) 126 (23): 182.

https://doi.org/10.1182/blood.V126.23.182.182

Published: 2015

Journal Articles

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

Kyle L. Runckel, BS, Cory Mavis, MSc, Joseph Skitzki, Juan J Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2015) 126 (23): 590.

https://doi.org/10.1182/blood.V126.23.590.590

Published: 2015

Journal Articles

Romidepsin in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A Case Series

Nikhil Mukhi, MD, Vaibhav Verma, MBBS, Anam Ahmed, MD, Hana Lim, MD, Jason Gonsky, MD PhD, Gurinder Sidhu, MD

Blood (2015) 126 (23): 5113.

https://doi.org/10.1182/blood.V126.23.5113.5113

Published: 2015

NARROW

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Serum Beta-2 Microglobulin Predicts the Survival Outcome after Autologous Stem Cell Transplantation in Relapse or Refractory Diffuse Large B Cell Lymphoma

High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Cost Consideration of Second Line Therapy for Relapsed Diffuse Large Lymphoma in the Community Setting

High-Dose Ara-C, Carboplatin, Etoposide, and Steroids (ACES) Is Effective in Relapse and Refractory Non-Hodgkin Lymphoma

Salvage Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

OPEC/Mpec for Adult T-Cell Leukemia/Lymphoma: A Single-Institution Study

AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

Immune System Profiling Following Autologous Stem Cell Transplant for High-Risk Neuroblastoma Predicts Disease-Free Survival

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

Romidepsin in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A Case Series

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only